Success for ReoPro competitor in stent trial
This article was originally published in Clinica
Executive Summary
Drug companies COR Therapeutics and Schering-Plough have stopped enrolment early in a study with the gpIIb/IIIa inhibitor antiplatelet agent, Integrilin (eptifibatide), after significant positive interim results were reported in patients undergoing elective angioplasty with stenting.